“The Glioblastoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period (2023-2032). Furthermore, launching various multiple- Glioblastoma pipeline products will significantly revolutionize the Glioblastoma market dynamics”
The Glioblastoma market report provides current treatment practices, Glioblastoma emerging drugs, market share of individual therapies, and current and forecasted 7MM Glioblastoma market size from 2019 to 2032. The report also covers current Glioblastoma treatment market practices/algorithms and unmet medical needs to curate the best opportunities and assess the market’s underlying potential.
Key Takeaways from the Glioblastoma Market Research Report
- The Glioblastoma market size in the 7MM is approximately USD 800 Million in 2021 and is projected to grow during the forecast period (2022-2032).
- The total Glioblastoma Market Size in the United States is expected to increase with a CAGR of 13.1% during the study period (2019–2032).
- The leading companies working in the Glioblastoma Market include VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.
- Promising Glioblastoma Pipeline Therapies in the various stages of development includes PLX3397, Temozolomide, VXM01, Cilengitide, ACT001, LAM561, TMZ, Onfekafusp alfa, and others.
- September 2023: Cantex Pharmaceuticals announced a study of phase 1 & 2 clinical trials for Azeliragon 5 mg. This is an open label study to determine the safety and preliminary evidence of a therapeutic effect of azeliragon in patients with newly diagnosed glioblastoma receiving concurrent radiation and temozolomide.
- September 2023: In8bio Inc. announced a study of phase 1 & 2 clinical trials for Autologous genetically modified gamma-delta T cells. This multicenter, Phase 1b/2 study is being conducted to determine if the experimental cell therapy is safe, tolerable and can delay the return of cancer in patients with a newly diagnosed or recurrent glioblastoma multiforme (GBM) in combination with standard chemotherapy treatment temozolomide (TMZ). If there is a 25% or greater improvement in survival in this study then the therapy should be studied further.
Discover more about therapies set to grab major Glioblastoma Market Share @ Glioblastoma Market Size
Glioblastoma Overview
A cancerous development of cells in the brain or spinal cord is the precursor to Glioblastoma. It can penetrate healthy tissue and wreak havoc there as it grows swiftly. The astrocytes that support nerve cells are the source of Glioblastoma development. Anyone can develop Glioblastoma at any age.
Glioblastoma Epidemiology Segmentation in the 7MM
- Total Glioblastoma Diagnosed Incident Population
- Glioblastoma Gender-specific Diagnosed Incidence
- Glioblastoma Type-specific Diagnosed Incidence
- Glioblastoma Age-specific Diagnosed Incidence
- Glioblastoma Diagnosed Incident Population based on Primary Site
- Glioblastoma Diagnosed Incident Population based on Histologic Classification
Download the report to understand which factors are driving Glioblastoma Epidemiology Trends @ Glioblastoma Epidemiological Insights
Glioblastoma Treatment Market
The Glioblastoma Treatment Market, a pivotal segment of the healthcare industry, encompasses the diverse array of therapies, drugs, and interventions designed to combat Glioblastoma, an aggressive and often fatal form of brain cancer. Glioblastoma Multiforme (GBM) is notorious for its resistance to conventional treatments, making research and development in this field crucial.
Glioblastoma Market Outlook
Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery.
To know more about Glioblastoma Treatment options, visit @ Glioblastoma Drugs
Glioblastoma Marketed Drugs
- Avastin: Genentech
- Temodar/Temodal: Merck
Glioblastoma Emerging Drugs
- Ofranergene obadenovec (VB-111): VBL Therapeutics
- Trans Sodium Crocetinate: Diffusion Pharmaceuticals
- Selinexor (KPT-330): Karyopharm Therapeutics
- VBI-1901: VBI Vaccines
- ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics
Learn more about the Glioblastoma Pipeline Therapies in clinical trials @ Glioblastoma Market Landscape
Scope of the Glioblastoma Market Research Report
- Coverage- 7MM
- Study Period- 2019-2032
- Glioblastoma Companies- VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics, Karyopharm Therapeutics, VBI Vaccines, Kazia Therapeutics, Aivita Biomedical, Medicenna Therapeutics, Kintara Therapeutics, Immunomic Therapeutics, Inovio Pharmaceuticals, and others.
- Glioblastoma Pipeline Therapies- PLX3397, Temozolomide, VXM01, Cilengitide, ACT001, LAM561, TMZ, Onfekafusp alfa, and others.
- Glioblastoma Market Dynamics: Glioblastoma Market Drivers and Barriers
- Glioblastoma Market Access and Reimbursement, Unmet Needs and Future Perspectives
Discover more about Glioblastoma Drugs in development @ Glioblastoma Ongoing Clinical Trials Analysis
Table of Content
1. Key Insights
2. Glioblastoma Market Report Introduction
3. Glioblastoma Market Overview at a Glance
4. Glioblastoma Epidemiology and Market Forecast Methodology
5. Executive Summary of Glioblastoma Multiforme (GBM)
6. Key Events
7. SWOT Analysis
8. Disease Background and Overview: Glioblastoma Multiforme
9. Glioblastoma Treatment
10. Guidelines and Recommendations from Different Organizations
11. Epidemiology and Patient Population
12. Patient Journey
13. Key Endpoints in Glioblastoma Multiforme
14. Glioblastoma Marketed Products
16. Glioblastoma: Seven Major Market Analysis
17. Glioblastoma KOL Views
18. Glioblastoma Unmet Needs
19. Glioblastoma Market Access and Reimbursement
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking